Perkins Coie Trust Co Has $5.33 Million Stock Position in Danaher Co. (NYSE:DHR)

Perkins Coie Trust Co boosted its position in Danaher Co. (NYSE:DHRFree Report) by 1.8% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 21,329 shares of the conglomerate’s stock after purchasing an additional 385 shares during the period. Danaher comprises 1.2% of Perkins Coie Trust Co’s holdings, making the stock its 22nd largest position. Perkins Coie Trust Co’s holdings in Danaher were worth $5,326,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Cape Investment Advisory Inc. acquired a new stake in Danaher during the fourth quarter worth approximately $25,000. BKM Wealth Management LLC acquired a new stake in Danaher during the fourth quarter worth approximately $27,000. Wetzel Investment Advisors Inc. acquired a new stake in Danaher during the fourth quarter worth approximately $29,000. Rakuten Securities Inc. acquired a new stake in Danaher during the fourth quarter worth approximately $36,000. Finally, Financial Connections Group Inc. acquired a new stake in Danaher during the fourth quarter worth approximately $41,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently issued reports on DHR shares. Citigroup lifted their price objective on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Barclays lifted their price target on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 24th. Robert W. Baird boosted their target price on shares of Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a report on Wednesday, April 24th. Bank of America boosted their target price on shares of Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a report on Wednesday, April 24th. Finally, Jefferies Financial Group started coverage on shares of Danaher in a report on Monday, June 3rd. They issued a “buy” rating and a $295.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $269.29.

View Our Latest Research Report on DHR

Insider Buying and Selling at Danaher

In other Danaher news, CEO Rainer Blair sold 47,175 shares of the stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the sale, the chief executive officer now owns 115,995 shares in the company, valued at approximately $28,908,273.90. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, CEO Rainer Blair sold 47,175 shares of the stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the transaction, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Alan G. Spoon sold 708 shares of the stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the transaction, the director now directly owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The disclosure for this sale can be found here. In the last 90 days, insiders sold 148,783 shares of company stock worth $37,536,717. Insiders own 11.10% of the company’s stock.

Danaher Stock Up 0.7 %

Shares of NYSE:DHR traded up $1.80 during midday trading on Monday, hitting $256.76. 3,121,261 shares of the company’s stock were exchanged, compared to its average volume of 2,844,678. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51. The stock has a 50 day moving average price of $254.80 and a 200-day moving average price of $245.88. The company has a market cap of $190.18 billion, a PE ratio of 43.52, a price-to-earnings-growth ratio of 3.80 and a beta of 0.85. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $269.11.

Danaher (NYSE:DHRGet Free Report) last posted its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The firm’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same period in the previous year, the firm posted $2.36 earnings per share. On average, sell-side analysts anticipate that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be paid a $0.27 dividend. The ex-dividend date is Friday, June 28th. This represents a $1.08 annualized dividend and a yield of 0.42%. Danaher’s dividend payout ratio (DPR) is 18.31%.

About Danaher

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Recommended Stories

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.